Envoy Medical Faces Nasdaq Delisting Hearing

The latest update is out from Envoy Medical ( (COCH) ).

Envoy Medical, Inc. received a deficiency notification from Nasdaq on February 25, 2025, due to not meeting the minimum market value of listed securities requirement. Despite a 180-day period to regain compliance, the company failed to meet the requirement by August 26, 2025, and requested a hearing to discuss potential pathways to compliance, including recent financial restructuring, though there is no assurance of a favorable outcome.

The most recent analyst rating on (COCH) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.

Spark’s Take on COCH Stock

According to Spark, TipRanks’ AI Analyst, COCH is a Underperform.

Envoy Medical’s overall stock score is primarily impacted by its poor financial performance, with significant negative profit margins and high leverage. Technical analysis indicates bearish momentum, and valuation metrics are unattractive due to ongoing losses. While recent corporate events provide some positive developments, they are insufficient to counterbalance the financial and technical challenges.

To see Spark’s full report on COCH stock, click here.

More about Envoy Medical

Average Trading Volume: 255,421

Technical Sentiment Signal: Strong Sell

Current Market Cap: $26.04M

For an in-depth examination of COCH stock, go to TipRanks’ Overview page.